ABSTRACT
With accumulating data on severe course of SARS-CoV-2/COVID-19 infection in children, it should be taken into account that immunocompromised patients are at increased risk of complications and death due to this disease. Currently vaccination is the only option to prevent the disease. Nowadays more and more data are coming on vaccination in children and in patients with immune deficiencies. In this paper, Polish National Consultants in pediatric oncology and hematology and clinical immunology present recommendations on vaccination in children with malignancies or after hematopoietic cell transplantation. These recommendations are based on ECIL-9 guidelines, adopted to national situation and updated with the latest information. With the fast changing knowledge and statements provided by Center for Disease Control (CDC), Food and Drug Administration (FDA) and European Med-icines Agency (EMA), such recommendations need to be regularly updated. Nevertheless, individual risk/benefit ratio should be always assessed for each patient, particularly in the case of the risk of poor immunological response to immunization.Copyright © 2021, Wydawnictwo Czelej Sp. z o.o.. All rights reserved.